ArticleSurgical endoscopy2025
Modified low-cost EndoVac is safe and efficacious for treatment of postoperative leaks even at low pressures.
Article in Surgical endoscopy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Indigenous endoscopic vacuum-assisted closure therapy for esophageal leaks: A novel technique.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026Article
- Endoscopic vacuum-assisted closure as a first-line treatment for post-esophagectomy anastomotic leaks: A paradigm shift in management.World journal of gastrointestinal surgery · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPostoperative gastrointestinal leaks are often treated using Endoscopic Vacuum therapy (EndoVac). We aim to study the role of modified low-cost EndoVac (mEndoVac) for treatment of postoperative leaks when used at low pressure for upper GI and standard pressure for lower GI leaks.
methodsRetrospective review of prospectively maintained endoscopy database from January 2022 till March 2024 was done for patients who underwent treatment for upper and lower GI leaks using mEndoVac. All upper GI leaks were treated with low pressure (25-30 mmHg-modulated using Sinapi™) while lower GI leaks were treated with standard high pressure (125-150 mmHg). The primary outcome was clinical success (resolution of leak cavity).
resultsEighteen patients underwent mEndoVac for anastomotic leaks (14 post-esophagectomy leaks, 4 rectal leaks). mEndoVac therapy was started at median 6 days after detection of leak. Intracavitatory mEndoVac placement was done in all patients. Median of 3.5 sessions (2-7) were done. Clinical success was achieved in 88.8% cases (16/18). Mortality at 6 months was seen in 3 cases (16.6%). Complications were seen in 5 (27.7%) patients (all mild).
conclusionsmEndoVac is safe and effective even at lower pressure for upper GI leaks and at standard pressure for lower GI leaks.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.